Search

Your search keyword '"Mäkisalo, Heikki"' showing total 172 results
Start Over Author "Mäkisalo, Heikki" Publication Year Range Last 10 years
172 results on '"Mäkisalo, Heikki"'

1. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study

Author

Boyd, Sonja, primary, Mustamäki, Taru, additional, Sjöblom, Nelli, additional, Nordin, Arno, additional, Tenca, Andrea, additional, Jokelainen, Kalle, additional, Rantapero, Tommi, additional, Liuksiala, Thomas, additional, Lahtinen, Laura, additional, Kuopio, Teijo, additional, Kytölä, Soili, additional, Mäkisalo, Heikki, additional, Färkkilä, Martti, additional, and Arola, Johanna, additional

Published
2024
Full Text
View/download PDF

3. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Author

Mäkisalo, Heikki, Huuhtanen, Riikka, Kosunen, Juhani, Leppä, Sirpa, Bono, Petri, Mattson, Johanna, Österlund, Emerik, Penttinen, Heidi, Mäkelä, Siru, Carpén, Olli, Timonen, Marjut, Lehtomäki, Kaisa, Salminen, Veera, Paunu, Niina, Vornanen, Martine, Lasse, Nieminen, Heervä, Eetu, Korkeila, Eija, Sutinen, Eija, Lavonius, Maija, Sundström, Jari, Mäkinen, Markus, Poussa, Tuija, Uutela, A., Ovissi, A., Hakkarainen, A., Ristimäki, A., Lundbom, N., Kallio, R., Soveri, L.M., Salminen, T., Ålgars, A., Halonen, P., Ristamäki, R., Nordin, A., Blanco Sequeiros, R., Rinta-Kiikka, I., Lantto, E., Virtanen, J., Pääkkö, E., Liukkonen, E., Saunavaara, J., Ryymin, P., Lammentausta, E., Osterlund, P., and Isoniemi, H.

Published
2021
Full Text
View/download PDF

6. High immune cell infiltration predicts improved survival in cholangiocarcinoma.

Author

Wirta, Erkki-Ville, Szeto, Säde, Koppatz, Hanna, Nordin, Arno, Mäkisalo, Heikki, Arola, Johanna, Sirén, Jukka, Ahtiainen, Maarit, Böhm, Jan, Mecklin, Jukka-Pekka, Sallinen, Ville, and Seppälä, Toni T.

Subjects
CHOLANGIOCARCINOMA, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, OVERALL survival, PROGNOSIS
Abstract

Background: Antitumoral immune response has a crucial role in constraining cancer. However, previous studies on cholangiocarcinoma (CCA), a rare and aggressive cancer, have reported contradictory findings on the prognostic impact of tumorinfiltrating T-lymphocytes. We aimed to clarify the effect of tumor-infiltrating CD3+ and CD8+ lymphocytes and PD-1/PD-L1 expression on CCA prognosis. Methods: CD3+, CD8+, and PD-1+ lymphocyte densities, as well as PD-L1 expression rate were analyzed from stained tissue microarray samples from the tumor center and invasive margin of 47 cholangiocarcinomas. The association of CD3+ and CD8+ based Immune cell score (ICS) and its components with overall survival was evaluated, adjusting for age, sex, TNM stage, radicality of surgery, tumor location, and PD-L1 expression on immune cells. Results: Low ICS was a strong independent prognostic factor for worse overall survival (Hazard ratio 9.27, 95% confidence interval 2.72-31.64, P<0.001). Among the ICS components, high CD8+ lymphocyte infiltration at the tumor center had the most evident impact on patient outcome. PD-1 and PD-L1 expression on immune cells did not have a significant impact on overall survival alone; however, PD-L1 positivity seemed to impair survival for ICSlow subgroup. Conclusion: Identifying patient subgroups that could benefit from immunotherapy with PD-1/PD-L1 pathway blockade may help improve treatment strategies for this aggressive cancer. Our findings highlight the importance of evaluating the immune contexture in cholangiocarcinoma, as ICS serves as a strong independent prognostic and selective factor for patients who might benefit from immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. The Helsinki approach to face transplantation

Author

Lindford, Andrew J, Mäkisalo, Heikki, Jalanko, Hannu, Lauronen, Jouni, Anttila, Veli-Jukka, Juteau, Susanna, Ämmälä, Antti-Jussi, Eskola, Anna, Saarni, Samuli, Isoniemi, Helena, Mäkitie, Antti, and Lassus, Patrik

Published
2019
Full Text
View/download PDF

9. The first 10 years of simultaneous pancreas‐kidney transplantation in Finland

Author

Ahopelto, Kaisa, primary, Sallinen, Ville, additional, Helanterä, Ilkka, additional, Bonsdorff, Akseli, additional, Grasberger, Juulia, additional, Beilmann‐Lehtonen, Ines, additional, Mäkisalo, Heikki, additional, Nordin, Arno, additional, Ortiz, Fernanda, additional, Savikko, Johanna, additional, Tukiainen, Eija, additional, Uutela, Aki, additional, Ekstrand, Agneta, additional, and Lempinen, Marko, additional

Published
2023
Full Text
View/download PDF

11. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Author

Schnitzbauer, Andreas A., Filmann, Natalie, Adam, René, Bachellier, Philippe, Bechstein, Wolf O., Becker, Thomas, Bhoori, Sherrie, Bilbao, Itxarone, Brockmann, Jens, Burra, Patrizia, Chazoullières, Olivier, Cillo, Umberto, Colledan, Michele, Duvoux, Christoph, Ganten, Tom M., Gugenheim, Jean, Heise, Michael, van Hoek, Bart, Jamieson, Neville, de Jong, Koert P., Klein, Christian G., Klempnauer, Jürgen, Kneteman, Norman, Lerut, Jan, Mäkisalo, Heikki, Mazzaferro, Vincenzo, Mirza, Darius F., Nadalin, Silvio, Neuhaus, Peter, Pageaux, George-Philippe, Pinna, Antonio D., Pirenne, Jaques, Pratschke, Johann, Powel, James, Rentsch, Markus, Rizell, Magnus, Rossi, Giorgio, Rostaing, Lionel, Roy, André, Scholz, Tim, Settmacher, Utz, Soliman, Thomas, Strasser, Simone, Söderdahl, Gunnar, Troisi, Roberto I., Turrión, Victor Sánchez, Schlitt, Hans J., and Geissler, Edward K.

Published
2020
Full Text
View/download PDF

14. Timing of Organ Procurement From Brain-Dead Donors Associates With Short- and Long-Term Outcomes After Liver Transplantation

Author

Eerola, Verner, Helanterä, Ilkka, Åberg, Fredrik, Lempinen, Marko, Mäkisalo, Heikki, Nordin, Arno, Isoniemi, Helena, Sallinen, Ville, Clinicum, HUS Abdominal Center, IV kirurgian klinikka, Pertti Panula / Principal Investigator, Department of Anatomy, and Helsinki University Hospital Area

Subjects
organ allocation, liver allograft function, Transplantation, Tissue and Organ Procurement, DURATION, graft survival, liver transplant dysfunction, Brain, donor hepatectomy, 3126 Surgery, anesthesiology, intensive care, radiology, Severity of Illness Index, Liver Transplantation, TIME, End Stage Liver Disease, ACTIVATION, procurement surgery, SURVIVAL, Humans, brain death, FAILURE
Abstract

Brain death-induced cytokine storm is thought to harm transplantable organs. However, longer procurement times have been associated with non-inferior or better outcomes in kidney, heart, and lung transplants, while optimal procurement time for liver allografts is unknown. Our aim was to analyze the association of time interval from brain death to organ procurement with liver allograft outcomes in two nationwide cohorts. The association of procurement interval with graft survival and short-term complications was analysed in multivariable models. Altogether 643 and 58,017 orthotopic liver transplantations from brain-dead donors were included from Finland between June 2004 and December 2017 and the US between January 2008 and August 2018, respectively. Median time from brain death to organ procurement was 10.5 h in Finland and 34.6 h in the US. Longer interval associated with better graft survival (non-linearly, p = 0.016) and less acute rejections (OR 0.935 95% CI 0.894–0.978) in the US cohort, and better early allograft function (p = 0.005; Beta −0.048 95% CI −0.085 −(−0.011)) in the Finnish cohort, in multivariable models adjusted with Donor Risk Index, recipient age, Model for End-Stage Liver Disease and indication for transplantation. Progressive liver injury after brain death is unlikely. Rushing to recover seems unnecessary; rest and repair might prove beneficial.

Published
2022

15. Gamma-glutamyltransferase predicts macrovesicular liver graft steatosis – an analysis of discarded liver allografts in Finland.

Author

Savikko, Johanna, Åberg, Fredrik, Tukiainen, Eija, Nordin, Arno, Mäkisalo, Heikki, Arola, Johanna, and Isoniemi, Helena

Subjects
GAMMA-glutamyltransferase, FATTY liver, FATTY degeneration, LIVER analysis, HOMOGRAFTS, LIVER
Abstract

Liver-transplantation activity is limited by the shortage of grafts. Donor-liver macrovesicular steatosis predisposes to ischemia-reperfusion injury and is associated with reduced graft survival. The increasing prevalence of fatty-liver disease underlines the importance of identifying macrovesicular steatosis in potential donor livers. We analyzed liver grafts discarded for transplantation, and particularly the role of gamma-glutamyltransferase (GGT) in predicting graft steatosis. One-hundred sixty rejected cadaveric-donor liver grafts were studied. Donor selection was based on clinical data, and macroscopic graft inspection. Discarded grafts were biopsied at procurement of non-liver organs. The most common reasons for discarding the graft were abnormal liver tests, ultrasound-verified steatosis and history of harmful alcohol use. GGT correlated moderately with macrovesicular steatosis (r = 0.52, p < 0.001), but poorly with microvesicular steatosis (r = 0.36, p < 0.001). Increased correlation between GGT and macrovesicular steatosis was observed among alcohol abusers (r = 0.67, p < 0.001). Area under the curve (AUC) of GGT for predicting >30% macrovesicular steatosis was 0.79 (95% CI 0.71–0.88), and for >60% steatosis, 0.79 (95% CI 0.68–0.90). The optimal GGT-cut off for detecting >30% and >60% macrovesicular steatosis were, respectively, 66 U/L (sensitivity 76% and specificity 68%) and 142 U/L (sensitivity 66% and specificity 83%). Among alcohol users, a GGT value >90 U/L showed 100% sensitivity for >60% macrovesicular steatosis. AUC for GGT in predicting fibrosis Stages 2–4 was 0.82 (95% CI 0.71–0.92, p < 0.001, optimal cut off 68, sensitivity 92%, specificity 61%). Abnormal liver values, steatosis and harmful alcohol use were the main reasons for discarding liver-graft offers in Finland. GGT proved useful in predicting moderate and severe liver graft macrovesicular steatosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis

Author

Werner, Jens M., Hornung, Matthias, Krah, Rubertha, Götz, Markus, Schnitzbauer, Andreas A., Schlitt, Hans J., Geissler, Edward K., Zülke, Carl, Lamby, Philipp E., Proneth, Andrea, Duvoux, Christophe, Burra, Patrizia, Jauch, Karl‐Walter, Rentsch, Markus, Ganten, Tom M., Schmidt, Jan, Settmacher, Utz, Heise, Michael, Rossi, Giorgio, Cillo, Umberto, Kneteman, Norman, Adam, René, Hoek, Bart, Bachellier, Philippe, Wolf, Philippe, Rostaing, Lionel, Bechstein, Wolf O., Rizell, Magnus, Powell, James, Hidalgo, Ernest, Gugenheim, Jean, Wolters, Heiner, Brockmann, Jens, Roy, André, Mutzbauer, Ingrid, Schlitt, Angela, Beckebaum, Susanne, Graeb, Christian, Nadalin, Silvio, Valente, Umberto, Turrión, Victor Sánchez, Jamieson, Neville, Scholz, Tim, Colledan, Michele, Fändrich, Fred, Becker, Thomas, Söderdahl, Gunnar, Chazouillères, Olivier, Mäkisalo, Heikki, Pageaux, Georges‐Philippe, Steininger, Rudolf, Soliman, Thomas, Jong, Koert P., Pirenne, Jacques, Margreiter, Raimund, Pratschke, Johann, Pinna, Antonio D., Hauss, Johann, Schreiber, Stefan, Strasser, Simone, Klempnauer, Jürgen, Troisi, Roberto I., Bhoori, Sherrie, Lerut, Jan, Bilbao, Itxarone, Klein, Christian G., Königsrainer, Alfred, Otto, Gerd, Mazzaferro, Vincenzo, Neuhaus, Peter, Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, and Neuhaus, P

Subjects
Silver Study, medicine.medical_specialty, Carcinoma, Hepatocellular, Silver, direct-acting antiviral agents, medicine.medical_treatment, 610 Medizin, Subgroup analysis, 030230 surgery, Liver transplantation, Gastroenterology, Group B, 03 medical and health sciences, HEPATOCELLULAR-CARCINOMA, hepatitis C virus infection, hepatocellular carcinoma, liver transplantation, 0302 clinical medicine, Internal medicine, Post-hoc analysis, medicine, Humans, Sirolimus, direct-acting antiviral agent, ddc:610, Transplantation, business.industry, Liver Neoplasms, Immunosuppression, medicine.disease, Hepatitis C, digestive system diseases, Calcineurin, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Neoplasm Recurrence, Local, business, medicine.drug
Abstract

Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n=88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n=78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression+CNIs for >50% (B1; n=44) or

Published
2020

18. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Author

Geissler, Edward K., Schnitzbauer, Andreas A., Zülke, Carl, Lamby, Philipp E., Proneth, Andrea, Duvoux, Christophe, Burra, Patrizia, Jauch, Karl-Walter, Rentsch, Markus, Ganten, Tom M., Schmidt, Jan, Settmacher, Utz, Heise, Michael, Rossi, Giorgio, Cillo, Umberto, Kneteman, Norman, Adam, René, van Hoek, Bart, Bachellier, Philippe, Wolf, Philippe, Rostaing, Lionel, Bechstein, Wolf O., Rizell, Magnus, Powell, James, Hidalgo, Ernest, Gugenheim, Jean, Wolters, Heiner, Brockmann, Jens, Roy, André, Mutzbauer, Ingrid, Schlitt, Angela, Beckebaum, Susanne, Graeb, Christian, Nadalin, Silvio, Valente, Umberto, Turrión, Victor Sánchez, Jamieson, Neville, Scholz, Tim, Colledan, Michele, Fändrich, Fred, Becker, Thomas, Söderdahl, Gunnar, Chazouillères, Olivier, Mäkisalo, Heikki, Pageaux, Georges-Philippe, Steininger, Rudolf, Soliman, Thomas, de Jong, Koert P., Pirenne, Jacques, Margreiter, Raimund, Pratschke, Johann, Pinna, Antonio D., Hauss, Johann, Schreiber, Stefan, Strasser, Simone, Klempnauer, Jürgen, Troisi, Roberto I., Bhoori, Sherrie, Lerut, Jan, Bilbao, Itxarone, Klein, Christian G., Königsrainer, Alfred, Mirza, Darius F., Otto, Gerd, Mazzaferro, Vincenzo, Neuhaus, Peter, and Schlitt, Hans J.

Published
2016
Full Text
View/download PDF

19. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Author

Uutela, A., primary, Ovissi, A., additional, Hakkarainen, A., additional, Ristimäki, A., additional, Lundbom, N., additional, Kallio, R., additional, Soveri, L.M., additional, Salminen, T., additional, Ålgars, A., additional, Halonen, P., additional, Ristamäki, R., additional, Nordin, A., additional, Blanco Sequeiros, R., additional, Rinta-Kiikka, I., additional, Lantto, E., additional, Virtanen, J., additional, Pääkkö, E., additional, Liukkonen, E., additional, Saunavaara, J., additional, Ryymin, P., additional, Lammentausta, E., additional, Osterlund, P., additional, Isoniemi, H., additional, Mäkisalo, Heikki, additional, Huuhtanen, Riikka, additional, Kosunen, Juhani, additional, Leppä, Sirpa, additional, Bono, Petri, additional, Mattson, Johanna, additional, Österlund, Emerik, additional, Penttinen, Heidi, additional, Mäkelä, Siru, additional, Carpén, Olli, additional, Timonen, Marjut, additional, Lehtomäki, Kaisa, additional, Salminen, Veera, additional, Paunu, Niina, additional, Vornanen, Martine, additional, Lasse, Nieminen, additional, Heervä, Eetu, additional, Korkeila, Eija, additional, Sutinen, Eija, additional, Lavonius, Maija, additional, Sundström, Jari, additional, Mäkinen, Markus, additional, and Poussa, Tuija, additional

Published
2021
Full Text
View/download PDF

21. Sopeutuminen - alistumista vai selviytymistä?

Author

Rapola, Janne, Heikinheimo, Oskari, Rovasalo, Aki, Mäkisalo, Heikki, Sisätautien osasto, Clinicum, Naistenklinikka, HUS Naistentaudit ja synnykset, HUS Vatsakeskus, and IV kirurgian klinikka

Subjects
3141 Terveystiede, Adaptation, Psychological, Environment, Pandemics, Illness Behavior
Abstract

Teema : sopeutuminen. Kuuntele podcast jossa Kari Hevossaari keskustelee joulunumeron päätoimittajan Janne Rapolan kanssa numeron teemasta sopeutumisesta.

Published
2021

27. Randomised sham-controlled double-blind trial evaluating remote ischaemic preconditioning in solid organ transplantation: a study protocol for the RIPTRANS trial

Author

Uutela, Aki, primary, Helanterä, Ilkka, additional, Lemström, Karl, additional, Passov, Arie, additional, Syrjälä, Simo, additional, Åberg, Fredrik, additional, Mäkisalo, Heikki, additional, Nordin, Arno, additional, Lempinen, Marko, additional, and Sallinen, Ville, additional

Published
2020
Full Text
View/download PDF

33. Maksaportin sappitiesyöpä eli Klatskinin tuumori

Author

Sallinen, Ville, Peltola, Katriina, Mäkisalo, Heikki, Pertti Panula / Vastuullinen tutkija, IV kirurgian klinikka, Clinicum, Syöpätautien osasto, HUS Syöpäkeskus, and HUS Vatsakeskus

Subjects
3122 Syöpätaudit, 3126 Kirurgia, anestesiologia, tehohoito, radiologia
Abstract

Teema : maksa- , haima- ja sappitiekirurgia. English summary

Published
2019

34. Kun Morgagni ja Caesar tapasivat

Author

Andersson, Saana, Mäkisalo, Heikki, HUS Sydän- ja keuhkokeskus, Sydän ja rintaelinkirurgia, Kirurgian osasto, HUS Vatsakeskus, and IV kirurgian klinikka

Subjects
3126 Kirurgia, anestesiologia, tehohoito, radiologia
Abstract

Teema : syntymä

Published
2019

35. Lääkärien pariutumisen motiivit

Author

Mustonen, Pekka, Pankakoski, Maiju, Arola, Johanna, Höckerstedt, Krister, Mäkisalo, Heikki, Saarela, Lauri, Lindgren, Leena, HUSLAB, Patologian osasto, Medicum, IV kirurgian klinikka, Clinicum, and HUS Vatsakeskus

Subjects
5144 Sosiaalipsykologia
Abstract

Teema : motivaatio

Published
2018

36. Motivoiko joulunumero?

Author

Höckerstedt, Krister, Arola, Johanna, Lindgren, Leena, Mustonen, Pekka, Mäkisalo, Heikki, Saarela, Lauri, IV kirurgian klinikka, Kirurgian osasto, Clinicum, Patologian osasto, Medicum, and HUS Vatsakeskus

Subjects
3111 Biolääketieteet, 3112 Neurotieteet
Abstract

Teema : motivaatio

Published
2018

40. Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis – a single‐center cohort study

Author

Wang, Yilin, primary, Keinonen, Anne, additional, Koskenmies, Sari, additional, Pitkänen, Sari, additional, Fyhrquist, Nanna, additional, Sadeghi, Mohammadreza, additional, Mäkisalo, Heikki, additional, Söderlund‐Venermo, Maria, additional, and Hedman, Klaus, additional

Published
2019
Full Text
View/download PDF

41. Cutavirus DNA in Malignant and Nonmalignant Skin of Cutaneous T-Cell Lymphoma and Organ Transplant Patients but Not of Healthy Adults

Author

Väisänen, Elina, primary, Fu, Yu, additional, Koskenmies, Sari, additional, Fyhrquist, Nanna, additional, Wang, Yilin, additional, Keinonen, Anne, additional, Mäkisalo, Heikki, additional, Väkevä, Liisa, additional, Pitkänen, Sari, additional, Ranki, Annamari, additional, Hedman, Klaus, additional, and Söderlund-Venermo, Maria, additional

Published
2018
Full Text
View/download PDF

42. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.

Author

Goeppert, Benjamin, Folseraas, Trine, Roessler, Stephanie, Kloor, Matthias, Volckmar, Anna‐Lena, Endris, Volker, Buchhalter, Ivo, Stenzinger, Albrecht, Grzyb, Krzysztof, Grimsrud, Marit M., Gornicka, Barbara, Seth, Erik, Reynolds, Gary M., Franke, Andre, Gotthardt, Daniel N., Mehrabi, Arianeb, Cheung, Angela, Verheij, Joanne, Arola, Johanna, and Mäkisalo, Heikki

Published
2020
Full Text
View/download PDF

43. Maksansiirto - voiko siirtoaiheita laajentaa?

Author

Isoniemi, Helena, Mäkisalo, Heikki, Nordin, Arno, Clinicum, IV kirurgian klinikka, and HUS Vatsakeskus

Subjects
Liver Cirrhosis, 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, Non-alcoholic Fatty Liver Disease, Contraindications, Patient Selection, Liver Neoplasms, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, +surgery, Hepatitis, Liver Transplantation
Abstract

Teema : elinsiirrot. English summary

Published
2017

44. Elinkauppa - elinsiirrot rikollisten käsissä

Author

Mäkisalo, Heikki, IV kirurgian klinikka, Clinicum, Kirurgian osasto, and HUS Vatsakeskus

Subjects
Tissue and Organ Procurement, Treatment Outcome, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, Living Donors, Organ Trafficking, +ethics, Organ Transplantation, +statistics & numerical data
Abstract

Teema : elinsiirrot. English summary

Published
2017

45. Nuoren naisen maksavamma

Author

Saarinen, Tuure, Mäkisalo, Heikki, Clinicum, II kirurgian klinikka, Kirurgian osasto, IV kirurgian klinikka, and HUS Vatsakeskus

Subjects
3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, Adolescent, Critical Care, Liver, +therapy, +diagnosis, Accidents, +injuries, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, Female, Abdominal Injuries, Horses
Abstract

English summary

Published
2017

46. Suomi 125 vuotta - elinsiirtoja edelleen?

Author

Jalanko, Hannu, Miettinen, Susanna, Mäkisalo, Heikki, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University, Lastenklinikka, Lastentautien yksikkö, Clinicum, IV kirurgian klinikka, Kirurgian osasto, HUS Lasten ja nuorten sairaudet, and HUS Vatsakeskus

Subjects
3126 Kirurgia, anestesiologia, tehohoito, radiologia, Organ Transplantation, +trends, Biokemia, solu- ja molekyylibiologia - Biochemistry, cell and molecular biology
Abstract

Teema : elinsiirrot

Published
2017

47. Kyykauden kuva

Author

Mäkisalo, Heikki, IV kirurgian klinikka, Clinicum, Kirurgian osasto, and HUS Vatsakeskus

Subjects
+adverse effects, 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, +therapy, +complications, Snake Bites, Viper Venoms
Published
2017

48. Incidence and long-term outcomes of surgically treated childhood hepatic malignancies in Finland.

Author

Tiusanen, Toivo, Hukkinen, Maria, Leskinen, Outi, Soini, Tea, Kanerva, Jukka A., Jahnukainen, Timo, Mäkisalo, Heikki, Heikinheimo, Markku, and Pakarinen, Mikko P.

Subjects
CARCINOMA, HEPATOCELLULAR carcinoma, MEDICAL records, SARCOMA, LIVER cancer
Abstract

Aim: To analyse incidence, treatment and outcomes of paediatric liver malignancies in Finland during 1987-2017.Methods: Medical records and national cancer registry data of 47 children with liver malignancies were reviewed. Survival was calculated with the Kaplan-Meier method.Results: During follow-up, liver malignancy incidence remained stable at 1.1:106 . Altogether, 42 patients with hepatoblastoma (n = 24), hepatocellular carcinoma (n = 11) and undifferentiated embryonal sarcoma (n = 7) underwent surgery at median age 4.6 (interquartile range, 2.0-9.6) years and were followed up for 13 (7.0-19) years. Cumulative 5-year survival was 86% for hepatoblastoma, 41% for hepatocellular carcinoma and 67% for undifferentiated embryonal sarcoma. Five-year survival was decreased among hepatoblastoma patients aged ≥ 2.4 years (73% versus 100%, P = .040), with PRETreatment EXTent of disease IV (PRETEXT, 60% vs 100%, P = .004), and with recurrent disease (67% vs 88%, P = .029). Recurrent/residual disease associated with decreased 5-year survival in hepatocellular carcinoma (0% vs 83%, P = .028). Survival was similar among 19 transplanted and 23 resected patients. In total, 14 deaths occurred either for the underlying malignancy (n = 8), adverse effects of chemotherapy (n = 5) or unrelated reasons (n = 1).Conclusion: Outcomes for PRETEXT I-III hepatoblastoma and un-metastasized hepatocellular carcinoma were encouraging. Adverse effects of chemotherapy significantly contributed to mortality. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results